Goat PRP14 (gPRP14) has xeno-antigenic properties and works as a vaccine in preclinical models of cancer.
Minucci, S.; Bussolati, B.; Massa, P.; Brossa, A.; Ravasio, R.; Saadeldin, M.; Degani, G.; Papadimitriou, E.; Saadeldin, A.; Salvaggio, A.; Visentin, C.; Rizzi, G.; Ricagno, S.; Popolo, L.; Vanoni, M. A.; Pelicci, P. G.
Show abstract
We studied the activity of recombinant goat PRP14 (gPRP14), a member of the RID protein family, as a xeno-antigen in preclinical models of cancer. Antisera from rabbits and mice immunized with gPRP14 showed strong reactivity against several tumor cell types, which was absent towards normal cells: the tumor selectivity was related to surface and intra-cellular expression in tumor cells, and to an exclusively intra-cellular localization in normal cells. In vitro, binding to tumor cells was followed by cytotoxicity which could be rescued by the addition of excess soluble antigen. In vivo, an anti-tumor activity of immunization with gPRP14 was observed in murine syngeneic models of breast cancer and melanoma: the anti-tumor response was present when gPRP14 was administered in a preventive setting, and persisted upon repeated challenges with tumor cells in long-term survivor mice. Finally, we showed that both the humoral and T-cell mediated responses are needed for the optimal anti-tumor effect in the murine melanoma model. Thus, we have performed an initial characterization of gPRP14 as a cancer vaccine, which -given the potential wide range of tumor cells positive for the antigen-appears as a promising, novel immunotherapy.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma 96%
- CXCR6 by increasing retention of memory CD8 T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer 96%
- Novel personalized cancer vaccine platform based on Bacillus Calmette-Guerin 96%
Similar papers in this journal
- CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts 96%
- Antibody Targeting of B7-H4 Enhances the Immune Response in Urothelial Carcinoma 94%
- Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses 94%
Similar papers in this journal
- A novel fully-human potency-matched dual cytokine-antibody fusion protein targets carbonic anhydrase IX in renal cell carcinomas 95%
- Platinum chemotherapy induces lymphangiogenesis in cancerous and healthy tissues that can be prevented with adjuvant anti-VEGFR3 therapy 95%
- High Affinity Chimeric Antigen Receptor with Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms 93%
Similar papers in this journal
- FSTL3 is a biomarker of poor prognosis and is associated with immunotherapy resistance in ovarian cancer. 94%
- Asparagine endopeptidase promotes radioresistance in breast cancer through ATR pathway modulation 92%
- Long-term patient-derived ovarian cancer organoids closely recapitulate tumor of origin and clinical response 92%
Similar papers in this journal
- Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory 96%
- PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma 95%
- Inflammasome- and gasdermin D-independent IL-1β production mobilizes neutrophils to inhibit antitumor immunity 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.